23 January 2018 - Cost regulators for NHS funded therapies in England and Wales have issued updated guidelines for the treatment of wet age-related macular degeneration, which continue to back use of both Bayer’s Eylea and Novartis’ Lucentis.

According to National Institute for Health and Care Excellence guidelines, intravitreal anti-vascular endothelial growth factor treatment should be offered for late AMD (wet active) for eyes with visual acuity within a specified range.

Lucentis (ranibizumab) or Eylea (aflibercept) can be considered a treatment option if: the best-corrected visual acuity is between 6/12 and 6/96; there is no permanent structural damage to the central fovea; the lesion size is less than or equal to 12 disc areas in greatest linear dimension; and there is evidence of recent presumed disease progression.

Read Pharma Times article